Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 109-118 , April 2009

Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study

  • William Insull Jr., MD

      Affiliations

    • Lipid Research Clinic, Baylor College of Medicine and Methodist Hospital, 1790 Dryden Rd., Room 8.08, Houston, TX 77030-3411 USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jan N. Basile, MD

      Affiliations

    • Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC USA
    • ,
  • Anthony N. Vo, MD

      Affiliations

    • Long Beach Veterans Affairs Medical Center, Long Beach, CA USA
    • ,
  • Ping Jiang, MS

      Affiliations

    • Abbott, Abbott Park, IL USA
    • ,
  • Roopal Thakkar, MD

      Affiliations

    • Abbott, Abbott Park, IL USA
    • ,
  • Robert J. Padley, MD

      Affiliations

    • Abbott, Abbott Park, IL USA

Received 10 September 2008 ,Accepted 8 February 2009.

References 

  1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  3. Violi F, Micheletta F, Iuliano L, MRC/BHF Heart Protection Study . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–714
  5. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622
  7. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786–798
  8. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70(suppl):3H–9H
  9. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  10. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996;276:544–548
  11. Jones GT, van Rij AM, Cole J, et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem. 2007;53:679–685
  12. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893–1900
  13. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  14. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003;14:298–305
  15. Assmann G. Beyond statin therapy: why we need new thinking. Curr Med Res Opin. 2005;21(suppl 6):S3–8
  16. Robinson JG. Simvastatin: present and future perspectives. Expert Opin Pharmacother. 2007;8:2159–2127
  17. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415–420
  18. The coronary drug project. Design, methods, and baseline results. Circulation. 1973;47(suppl 3):I1–150
  19. Niaspan (package insert). Abbott Laboratories, North Chicago, IL, 2005.
  20. Zocor (package insert). Merck, Sharp, & Dohme, LTD, Cramlington, Northumberland, UK, 2007.
  21. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  22. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  24. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens. 2003;21:1291–1298
  25. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;8:69–81
  26. Simcor (package insert). Abbott Laboratories, North Chicago, IL, 2008.
  27. Lipitor (package insert). Pfizer Ireland Pharmaceuticals, Dublin, Ireland, 2007.
  28. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101:1428–1436
  29. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2:79–90
  30. Brinton EA, Vo A, Kashyap ML, Thakkar R, Padley RJ, Jiang P. Aspirin and a new formulation of niacin, extended-release, can reduce flushing incidence, duration, and severity. 2008 National Lipid Association Annual Scientific Congress, May 29–June 1, 2008, Seattle, WA.

PII: S1933-2874(09)00084-1

doi: 10.1016/j.jacl.2009.02.009

Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 109-118 , April 2009

Article Tools

* Image Usage & Resolution